News
February 23, 2026: State investigates whistleblower allegations of unsafe GLP-1 drug handling at Mochi Health-affiliated pharmacy.
Washington State investigators found serious violations at a Mochi Health-affiliated compounding pharmacy producing GLP-1s, and a med spa bill in Indiana hears public testimony about a med spa bill.
[...]Are dead insects in manufacturing areas enough to disqualify a firm from the FDA’s Green List for makers of GLP-1 API?
Industry experts told us that these two companies are on the FDA’s Green List, despite problematic inspections in late 2024 and early 2025. Learn what the inspectors found.
[...]Update on drug importation, February 2026
Well-meaning advocates continue to propose importing medicine from foreign countries to lower drug prices for Americans. Past efforts didn’t pay off financially and raised public health risks. Here’s the state of this issue today.
[...]February 17, 2026: Pennsylvania compounding pharmacy earns another FDA warning letter
A Pennsylvania compounding pharmacy received another FDA warning letter following a series of enforcement actions, including a $1 million state fine in October.
[...]Prescription drug freight fraud report, January 2026
The last two months of 2025 saw thousands of shipments of drugs popularized by social media imported into the U.S., as well as Xarelto and antibiotics. The shipments carried a wide range of product codes; some appropriate, and others far less so.
[...]PSM gives testimony in opposition to a Colorado bill to permit alternative funding programs
On February 17, PSM submitted written and oral testimony in opposition to Colorado HB26-1056, which would permit self-insured employers to use alternative funding programs to import foreign medicines from outside the U.S. drug supply chain.
[...]Pill press update: July 2025 through January 2026
Unregulated pill presses and molds make fake pills with dangerous and even deadly consequences for thousands of people every year. Read our July 2025 to January 2026 update about pill press seizures, policy developments, and legislation.
[...]FDA Alert: Abbott FreeStyle Libre 3 and Libre 3 Plus Continuous Glucose Monitor Recall
The FDA has posted a notice about the recall of continuous glucose monitors from Abbott.
[...]February 9, 2026: PBMs are the target of the spending bill and the FTC investigation
The federal spending package that ended January’s government shutdown will prohibit PBMs from linking rebates to drug companies’ list prices. The FTC reported that PBMs inflated the prices of generic drugs.
[...]FDA Alert: Dietary supplement recall due to undeclared drug ingredient
The FDA has posted a notice for a dietary supplement recalls involving products found to contain undeclared pharmaceutical ingredients.
[...]